BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

...anti-PDL1 in non-small cell lung cancer.TARGETSCTLA-4 (CTLA4; CD152) – Cytotoxic T-lymphocyte associated protein 4PD-L1 (B7-H1; CD274) Programmed cell death 1...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...a partner that could compete in the PD-1...
...telangiectasia and Rad3 relatedPD-L1 (B7-H1; CD274) – Programmed cell death 1...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

...three biosimilar approvals in China and entered several global partnerships, including out-licensing ex-China rights to PD-1...
...Hengrui Medicine Co. Ltd. (Shanghai:3600276) took the honors as Commercial Achievement of the Year.  The anti-PD-1...
...and the U.S. Zenni Optical won the award in the corporate category.TARGETSPD-1 (PDCD1; CD279) – Programmed cell death 1 Hongjiang...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...receptor FGFR – Fibroblast growth factor receptor PD-1 PD-1  (PDCD1; CD279...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...vasculature into tumor tissue. Rüdiger added that standard mouse cell lines that are typically susceptible to PD-1...
...during the initial cycle to assess acute toxicity, but then progress to a combination with PD-1...
...– GDNF family receptor alpha likeICAM-1 (CD54) – Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1 (PDCD1; CD279) – Programmed cell death 1 Stephen...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...factor receptorIL-2 – Interleukin-1PD-L1 (B7-H1; CD274) – Programmed cell death 1...
BioCentury | Nov 10, 2020
Product Development

First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target

Data presented at the annual CTAD meeting hint that anti-tau therapy semorinemab from Genentech and AC Immune may have engaged its target yet failed to decrease tau aggregation in a Phase II study to treat...
BioCentury | Nov 7, 2020
Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

...Apollomics’ board.The company has immuno-oncology antibodies targeting PD-1...
...HER1) - Epidermal growth factor receptorPD-1 (PDCD1; CD279...
...Programmed cell death 1PD-L1 (B7-H1; CD274) - Programmed cell death 1...
Items per page:
1 - 10 of 4880